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Abstract 
Background: The excessive accumulation of extracellular matrix of hepatic fibrosis is positively correlated with tis‑
sue inhibitors of metalloproteinase 1 (TIMP1). Here we aimed to investigate whether TIMP1 may be down‑regulated 
by Decoy ODNs strategy to capture transcriptional factor upstream TIMP1 element 1 (UTE1) and specificity protein 
1(SP1).
Results: By luciferase reporter assays, we confirmed that these Decoy ODNs could influence the promoter activation 
of TIMP‑1, α‑SMA and Collagen Iα2 (COLΙα2) genes as well as the enhancer activation of TRE in HSC‑T6 cells, and the 
combination tended to be more effective than SP1 or UTE1 Decoy ODN alone. Western blot analysis also demon‑
strated down‑regulation of the expression of those target genes except for TGF‑β. Furthermore, we observed that the 
viability of HSC‑T6 cells at 72 h was significantly in decline in combination group.
Conclusion: The combination of SP1 and UTE1 Decoy ODNs treatments inhibit the activation and proliferation of 
HSCs more effectively than one of the Decoy ODNs through co‑regulation of TIMP1 and TGF‑β signal pathway but not 
the expression of TGF‑β itself.
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Background
Hepatic fibrosis is a common pathological progress into 
cirrhosis, which often leads to the death of the patient 
without liver transplantation, in a variety of liver diseases. 
A growing body of evidence indicates that hepatic fibro-
sis and even cirrhosis can be at least partially resolved 
when the disease cause is effectively prevented. However, 
the mechanisms of hepatic fibrosis and cirrhosis are still 
not completely understood, and there is no approved 
therapy yet to reverse this progression [1].
Hepatic fibrosis is characterized with the accumulation 
of extracellular matrix (ECM), including collagens, gly-
coproteins, and proteoglycans, and hepatic stellate cells 
(HSCs) are the major cells involved in ECM metabolism 
[2]. In normal liver, HSCs perform physiological func-
tion as the major hepatic store for retinoid in the space 
of Disse. In response to liver injury, HSCs go through 
progressive phenotypic transformation to proliferating 
myofibroblast-like cells [3] under stimulated with fibrotic 
cytokines and inflammatory cytokines, such as TGF-β, 
CTGF, PDGF [4, 5]. The activation of HSCs is character-
ized by loss of vitamin A droplets, expression of smooth 
muscle α-actin (α-SMA) [6] and generation a lot of ECM 
[7] for epithelial to mesenchymal transition (EMT) [8]. 
When engaged with high oxidized cholesterol level, the 
expression of the profibrogenic factor tissue inhibitors of 
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metalloproteinase 1 (TIMP1), which prevents ECM being 
degraded by forming an inhibitory complex with the 
matrix metalloproteinases (MMPs) [9] and accelerates 
cell proliferation in a large-scale of cell types independent 
of its MMP-inhibitory activity [10], was also significantly 
up-regulated as well as TGF-β in HSCs of mice [11]. The 
expression of these hepatic fibrosis related genes are reg-
ulated by some transcription factors, such as specificity 
protein 1 (SP1), NF-κB, Smads, upstream TIMP1 element 
1 (UTE1).
Decoy ODN is a short DNA segment from 10 to 30 bp 
including transcription factor binding site (TFBS) [12], 
which can competitively bind transcription factor and 
prevent the transcription factor binding to TFBS of tar-
get genes effectively,thus the Decoy ODNs strategy 
influences the expression of target genes through block-
ing mRNA transcription at the DNA level [13]. SP1 has 
highly homologous zinc-finger domains in the C-termi-
nal region binding GC or GT boxes and glutamine-rich 
domains for transcriptional activation in the N-terminus. 
It regulates the expression of genes, including not only 
housekeeping genes, but also the tissue-specific gene 
[14]. SP1 is involved in the expression of ECM genes that 
have an important role in hepatic fibrosis progress and 
regulates expression of several genes that are relevant to 
downstream targets of TGF-β [15]. In addition, the over-
expression of SP1 can also inhibit matrix metalloprotein-
ase-9 (MMP-9) transcription, thus preventing matrix 
degradation [16]. SP1 Decoy ODN could inhibit the 
activation of HSCs [17]. UTE1 is an essential regulatory 
DNA motif for the activity of TIMP1 promoter in HSCs 
[18] and there is no report using UTE1 Decoy ODN to 
inhibit the activity of TIMP1 promoter yet.
There are GC-rich motifs binding for SP1 and TFBS for 
UTE1 on the TIMP1 promoter sequence inspiring us to 
explore whether combination of SP1 and UTE1 Decoy 
ODNs treatments can inhibit the activation of HSCs 
through capturing SP1 and UTE1 to down-regulate the 
activation of TIMP1. To test this hypothesis, we ana-
lyzed the influences of the combination of SP1 and UTE1 
Decoy ODNs on the activation of promoter TIMP1 and 
the expression of TIMP1. Besides, we also analyzed the 
influences on TRE and the hepatic fibrosis related genes, 
Collagen Iα2 (COLΙα2), α-SMA, TGF-β, as well as the 
proliferation of HSC-T6 cells.
Results
The expression of TIMP1 was downregulated by SP1 
and UTE1 Decoy ODNs treatment in HSC‑T6 cells
There are three binding sites for transcription factor SP1 
and one binding site for transcription factor UTE1 in the 
promoter of TIMP1 through bioinformatics analysis. To 
determine whether SP1 and UTE1 Decoy ODNs influ-
ence the activity of the promoter of TIMP1, we con-
structed plasmid pGLuc-P-TIMP1 which is Gaussia 
luciferase report gene for the promoter of TIMP1 and 
the results showed it was activated in HSC-T6 cells com-
pared to mock (Fig. 1). After pGLuc-P-TIMP1 was trans-
fected into HSC-T6 cells for 24  h, Decoy ODNs were 
transfected into HSC-T6 cells for another 24  h and the 
results showed all luciferase activities of the pGLuc-P-
TIMP1 obviously decreased (p  <  0.01) in three experi-
mental groups (SP1 Decoy ODN group, UTE1 Decoy 
ODN group, mixture group of SP1 and UTE1 Decoy 
ODNs), respectively, compared to Scr Decoy ODN 
group. The results also showed the luciferase activities of 
the pGLuc-P-TIMP1 in mixture group of SP1 and UTE1 
Decoy ODNs decreased compared with SP1 Decoy ODN 
group (p < 0.01) and UTE1 Decoy ODN group (p < 0.05), 
respectively (Fig.  1), suggesting the combination of SP1 
and UTE1 Decoy ODNs can further inhibit the activation 
of promoter of TIMP1 than either of them.
To further certify SP1 and UTE1 Decoy ODNs influ-
ence on the expression of the TIMP1 in the activated 
HSCs, we transfected Decoy ODNs into HSC-T6 cells 
for 48 h and tested the expression of the TIMP1 through 
quantification of western blot assays, no evident decrease 
was observed in SP1 Decoy ODN group (p  >  0.05) or 
Decoy ODN UTE1 group (p > 0.05) compared to scram-
ble control, respectively. Nevertheless, there was sig-
nificant decrease in TIMP1 expression dealing with the 
combination of SP1 and UTE1 Decoy ODNs, not only 
compared to scramble control (p < 0.01), but also com-
pared with SP1 Decoy ODN (p  <  0.05) or UTE1 Decoy 
ODN groups (p < 0.05), respectively (Fig. 2a, b).
To explore whether the expression of MMP2 and 
MMP9 in activated HSCs is down-regulated by SP1 and 
UTE1 Decoy ODNs, Decoy ODNs were also transfected 
into HSC-T6 cells for 48 h again. Not only SP1 or UTE1 
Decoy ODNs, but also combination of SP1 and UTE1 
Decoy ODNs could not down-regulate the expression 
of MMP2 (p > 0.05) and MMP9 (p > 0.05) compared to 
scramble control (Fig. 2a, c, d) through quantification of 
western blot assays.
SP1 and UTE1 Decoy ODNs treatment decreased COLΙα2 
synthesis in HSC‑T6 cells
Bioinformatics analysis found that there are two binding 
sites for transcription factor SP1 and no binding site for 
transcription factor UTE1 in the promoter of COLΙα2. 
To explore the influence on the activity of promoter of 
COLΙα2 by SP1 and UTE1 Decoy ODNs, the Gaussia 
luciferase report gene plasmid pGLuc-P-COLΙα2 for the 
promoter of COLΙα2 was constructed and the results 
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showed it was activated in HSC-T6 cells comparing with 
mock (Fig.  3a). After pGLuc-P-COLΙα2 was transfected 
into HSC-T6 cells for 24  h, Decoy ODNs were trans-
fected into HSC-T6 cells for another 24 h and the results 
showed all luciferase activities of the pGLuc-P-COLΙα2 
evidently decreased (p < 0.01; p < 0.01; p < 0.05) in three 
experimental groups (SP1 Decoy ODN group, UTE1 
Decoy ODN group, mixture group of SP1 and UTE1 
Decoy ODNs), respectively, compared to Scr Decoy ODN 
group. However, there was no obvious difference in the 
luciferase activities of the pGLuc-P-COLΙα2 in mixture 
group of SP1 and UTE1 Decoy ODNs compared with 
SP1 Decoy ODN group (p > 0.05) or UTE1 Decoy ODN 
group (p > 0.05), respectively (Fig. 3a).
To further certify whether SP1 and UTE1 Decoy ODNs 
can down-regulate the expression of COLΙα2 in activated 
HSCs, Decoy ODNs were also transfected into HSC-
T6 cells for 48  h. The results were analyzed by western 
blot and showed the expression of the COLΙα2 signifi-
cant decrease (p  <  0.05) dealing with SP1 Decoy ODN. 
However, there was no obvious difference (p  >  0.05) 
between UTE1 Decoy ODN and scramble control. More-
over, there was significant decrease in COLΙα2 expres-
sion dealing with combination of SP1 and UTE1 Decoy 
ODNs, not only compared to scramble control (p < 0.01), 
but also compared with SP1 Decoy ODN (p  <  0.05) 
or UTE1 Decoy ODN groups (p  <  0.05), respectively 
(Fig. 4a, b).
α‑SMA expression was downregulated by SP1 and UTE1 
Decoy ODNs in HSC‑T6 cells
α-SMA is an important marker of activated HSCs. To 
explore the influence of SP1 and UTE1 Decoy ODNs on 
the activity of promoter of α-SMA, we found four bind-
ing sites for transcription factor SP1 and no binding site 
for transcription factor UTE1 in the promoter of α-SMA 
through bioinformatics analysis. When plasmid pGLuc-
PSMA which is Gaussia Luciferase report gene for the 
promoter of α-SMA was transfected into HSC-T6 cells, 
the luciferase activity increased comparing with mock 
(Fig. 3b). After pGLuc-PSMA was transfected into HSC-
T6 cells for 24  h, Decoy ODNs were transfected into 
HSC-T6 cells for another 24  h and the results showed 
all luciferase activities of the pGLuc-PSMA obviously 
decreased (p  <  0.01) in three experimental groups (SP1 
Decoy ODN group, UTE1 Decoy ODN group, mixture 
group of SP1 and UTE1 Decoy ODNs), respectively, 
compared to Scr Decoy ODN group. There were obvi-
ous decreases in the luciferase activities of the pGLuc-
PSMA in mixture group of SP1 and UTE1 Decoy ODNs 
compared to SP1 Decoy ODN group (p < 0.01) or UTE1 
Decoy ODN group (p < 0.01), respectively (Fig. 3b).
To further certify whether SP1 and UTE1 Decoy ODNs 
can down-regulate the expression of α-SMA in activated 
HSCs, Decoy ODNs were also transfected into HSC-T6 
cells for 48 h. The results were analyzed by western blot 
and showed the expression of the α-SMA significant 
Fig. 1 Influence of SP1 and UTE1 Decoy ODNs on the activity of promoter of TIMP1 in HSC‑T6 cells. After pGLuc‑P‑TIMP1 was transfected into HSC‑
T6 cells for 24 h, Decoy ODNs were transfected for another 24 h. Data are presented as the mean ± SD of three experiments and each experiment 
for three wells. ΔΔp < 0.01 represented three experimental groups compared to Scr Decoy ODN group respectively. *p < 0.05 and **p < 0.01
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decrease dealing with only SP1 Decoy ODN (p  <  0.05) 
or UTE1 Decoy ODN (p  <  0.05), compared to scram-
ble control, respectively. Notably, the expression sharply 
decreases, dealing with the combination of SP1 and 
UTE1 Decoy ODNs, not only compared to scramble con-
trol (p  <  0.01), but also compared to SP1 Decoy ODN 
(p  <  0.05), respectively. However, there was no obvious 
difference (p > 0.05) between mixture group of SP1 and 
UTE1 Decoy ODNs and group of UTE1 Decoy ODN 
(Fig. 4a, c).
SP1 and UTE1 Decoy ODNs had no affect on TGF‑β 
expression, but suppressed TRE activity partly in HSC‑T6 
cells
There are thirteen binding sites for transcription factor 
SP1 and no binding site for transcription factor UTE1 
in the promoter of TGF-β through bioinformatics anal-
ysis. To explore the influence of SP1 and UTE1 Decoy 
ODNs on the expression of TGF-β, Decoy ODNs were 
also transfected into HSC-T6 cells for 48  h. The results 
were analyzed by western blot and showed the expression 
of the TGF-β was not influenced, not only in the group 
of SP1 Decoy ODN (p > 0.05) or group of UTE1 Decoy 
ODN (p  >  0.05), but also in the mixture group of SP1 
and UTE1 Decoy ODNs (p > 0.05), compared to scram-
ble control, respectively. In addition, there was no obvi-
ous difference between mixture group of SP1 and UTE1 
Decoy ODNs and group of SP1 Decoy ODN (p  >  0.05) 
or group of UTE1 Decoy ODN (p  >  0.05), respectively 
(Fig. 5a, b).
To explore the influence of SP1 and UTE1 Decoy ODNs 
on TRE, plasmid pGLuc-TRE-MiniTK which is Gaussia 
Luciferase report gene for the TRE was transfected into 
HSC-T6 cells and the result showed it was activated in 
HSC-T6 cells (Fig.  5c). After pGLuc-TRE-MiniTK was 
transfected into HSC-T6 cells for 24 h, Decoy ODNs were 
transfected into HSC-T6 cells for another 24  h and the 
results showed all luciferase activities of the pGLuc-TRE-
MiniTK decreased obviously (p  <  0.01) in three experi-
mental groups (SP1 Decoy ODN group, UTE1 Decoy 
Fig. 2 The expression of TIMP1, MMP2 and MMP9 dealed with SP1 and UTE1 Decoy ODNs by western blot assay. D-SP1 SP1 Decoy ODN, D-UTE1 
UTE1 Decoy ODN, Scramble Scr Decoy ODN. Data are presented as the mean ± SD of three experiments. *p < 0.05 and **p < 0.01. The β‑actin 
protein served as control and band intensities were normalized to β‑actin in the quantificative analysis. a The expression of TIMP1, MMP2 and MMP9 
were analysed by western blot assay when SP1 and UTE1 Decoy ODNs were transfected into HSC‑T6 cells for 48 h. b Quantification of TIMP1 expres‑
sion in HSC‑T6 cells by western blot showed an obvious decrease (p = 0.001) in average band intensity with mixture group of SP1 and UTE1 Decoy 
ODNs, compared with scramble control, while quantification of TIMP1 expression did not show significant decreases comparing group of SP1 
Decoy ODN (p = 0.153) or group of UTE1 Decoy ODN (p = 0.071) to scramble control, respectively. There are significant decreases comparing group 
of mixture group of SP1 and UTE1 Decoy ODNs with group of SP1 Decoy ODN (p = 0.026) and group of UTE1 Decoy ODN (p = 0.036), respectively. 
c Quantification of MMP2 expression in HSC‑T6 cells by western blot did not show significant changes (p > 0.05) among them. d Quantification of 
MMP9 expression in HSC‑T6 cells by western blot did not show significant changes (p > 0.05) among them
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ODN group, mixture group of SP1 and UTE1 Decoy 
ODNs) compared to Scr Decoy ODN group, respectively. 
However, no evidence supported the luciferase activity 
of the pGLuc-TRE-MiniTK in mixture group of SP1 and 
UTE1 Decoy ODNs had any distinction compared with 
SP1 Decoy ODN group (p > 0.05) and UTE1 Decoy ODN 
group (p > 0.05), respectively (Fig. 5c).
Combination SP1 and UTE1 Decoy ODNs treatment 
inhibited proliferation of HSC‑T6 cells
To explore whether SP1 and UTE1 Decoy ODNs can 
inhibit the proliferation of HSC-T6 cells, Decoy ODNs 
were transfected into HSC-T6 cells for 24, 48 and 72  h 
and the proliferation of HSC-T6 cells were checked by 
MTT assay. The results showed that all experimental 
Fig. 3 Influence of SP1 and UTE1 Decoy ODNs on the activity of promoters of COLIα2 and α‑SMA in HSC‑T6 cells. a After pGLuc‑P‑COLIα2 or b 
pGLuc‑PSMA was transfected into HSC‑T6 cells for 24 h, Decoy ODNs were transfected for another 24 h. Data are presented as the mean ± SD of 
three experiments and each experiment for three wells. ΔΔp < 0.01 and Δp < 0.05 three experimental groups compared to Scr Decoy ODN group 
respectively. **p < 0.01
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Fig. 4 The expression of COLIα2 and α‑SMA dealed with SP1 and UTE1 Decoy ODNs by Western blot assay. D-SP1 SP1 Decoy ODN, D-UTE1 UTE1 
Decoy ODN, Scramble Scr Decoy ODN. Data are presented as the mean ± SD of three experiments. Δp < 0.05 and ΔΔp < 0.01 represented three 
experimental groups compared to Scr Decoy ODN group respectively. *p < 0.05 and **p < 0.01. The β‑actin protein served as control and band 
intensities were normalized to β‑actin in the quantificative analysis. a The expression of COLIα2 and α‑SMA was analysed by western blot assays 
when SP1 and UTE1 Decoy ODNs were transfected into HSC‑T6 cells for 48 h. b Quantification of COLIα2 expression in HSC‑T6 cells by western blot 
showed a significant decrease (p = 0.034) in average band intensity with group of SP1 Decoy ODN, however, there was not obvious difference from 
group of UTE1 Decoy ODN (p = 0.220), compared to scramble control, respectively. There are significant decreases comparing group of combi‑
national treatment of SP1 and UTE1 Decoy ODNs, not only to scramble control (p = 0.001), but also with group of SP1 Decoy ODN (p = 0.044) 
or group of UTE1 Decoy ODN (p = 0.030), respectively. c Quantification of α‑SMA expression in HSC‑T6 cells by western blot showed obvious 
decreases (p = 0.020; p = 0.010; p = 0.000) in average band intensity with three experimental groups (SP1 Decoy ODN group, UTE1 Decoy ODN 
group, mixture group of SP1 and UTE1 Decoy ODNs) compared with scramble control, respectively. There was a significant decrease (p = 0.045) 
comparing mixture group of SP1 and UTE1 Decoy ODNs with SP1 Decoy ODN group, however, there was no obvious difference (p = 0.179) com‑
pared to UTE1 Decoy ODN group, respectively
Fig. 5 Influnce of SP1 and UTE1 Decoy ODNs on TGF‑β and TRE in HSC‑T6 cells. a Influnce of SP1 and UTE1 Decoy ODNs on the expression of TGF‑β 
by western blot assays in HSC‑T6 cells. The β‑actin protein served as control. D-SP1 SP1 Decoy ODN, D-UTE1 UTE1 Decoy ODN, Scramble Scr Decoy 
ODN. b Quantification of TGF‑β expression in HSC‑T6 cells by western blot did not show significant changes (p > 0.05) among the groups. Data are 
presented as the mean ± SD of three experiments. The band intensities were normalized to β‑actin in the quantificative analysis. c Influence of SP1 
and UTE1 Decoy ODNs on the activity of TRE in HSC‑T6 cells. After pGLuc‑TRE‑MiniTK was transfected into HSC‑T6 cells for 24 h, Decoy ODNs were 
transfected for another 24 h. Data are presented as the mean ± SD of three experiments and each experiment for three wells. ΔΔp < 0.01 repre‑
sented three experimental groups compared to Scr Decoy ODN group respectively. **p < 0.01
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groups had no obvious effect on the proliferation of HSC-
T6 cells at 24 or 48  h. However, the survival rate obvi-
ously declined (p < 0.01) in SP1 Decoy ODN group and 
UTE1 Decoy ODN group at 72 h, compared to Scr Decoy 
ODN group, respectively. After SP1 and UTE1 Decoy 
ODNs were delivered together into HSC-T6 cells for 
72 h, we found the cell survival rate was below 0.6, obvi-
ously declined compared with SP1 Decoy ODN group 
(p < 0.01) or UTE1 Decoy ODN group (p < 0.01), respec-
tively (Fig. 6).
Discussion/conclusion
HSCs play an important role in the progression of liver 
fibrosis when they activated and differentiated into 
myofibroblast cells which can synthesize ECM along with 
the expression of marker molecule α-SMA [19]. It is well 
known that over deposition of ECM can impair the liver 
function and collagen is the main component of ECM 
produced by activited HSCs [20]. In activated HSCs, 
down-regulation of SP1 is able to inhibit the proliferation 
and the expression of TGF-β, α-SMA and Smad4 [21]. In 
human hypertrophic scar fibroblasts, SP1 Decoy ODN 
can significantly reduce the secretion of collagen [22]. 
Blocking the effect of SP1 by SP1 Decoy ODN inhibits 
COLIα2 promoter activity in NIH 3T3 fibroblasts [23]. 
SP1 Decoy ODN can inhibit the activation of HSCs via 
down-regulating the expression of hepatic fibrosis related 
genes, such as TGF-β, PDGF-BB, α-SMA, Collagen Iα1 
(COL Iα1) and TIMP1 [17]. Our study indicated the 
activity of promoter of α-SMA and COLIα2 genes and 
these genes expression can be inhibited by SP1 or UTE1 
Decoy ODNs or their combination. In renal tubulointer-
stitial fibrosis, Smad/SP1 chimeric Decoy ODN have a 
more significantly inhibitory effect on EMT and fibrosis 
compared with Smad or SP1 Decoy ODNs [24]. In our 
study, we also proved it was more efficient for the com-
bination of SP1 and UTE1 Decoy ODNs in inhibiting the 
activity of promoter of α-SMA gene and the expression 
of α-SMA and COLIα2 than one of Decoy ODNs. We 
cannot ignore the fact that GC-rich motifs exist in the 
promoters of α-SMA and COLIα2 genes, but none bind-
ing sites for transcription factor UTE1 by bioinformatics 
Fig. 6 Inhibitory effect of SP1 and UTE1 Decoy ODNs on the proliferation of HSC‑T6 cells. a After SP1 and UTE1 Decoy ODNs were transfected 
into HSC‑T6 cells at 24, 48 and 72 h, the proliferation of cells were checked by MTT. b After Decoy ODNs transfected into HSC‑T6 cells for 72 h, the 
survival rate obviously declined (p < 0.01) in SP1 Decoy ODN group and UTE1 Decoy ODN group at 72 h, compared to Scr Decoy ODN group. Data 
are presented as the mean ± SD of three experiments and each experiment for three wells. ΔΔp < 0.01 represented three experimental groups 
compared to Scr Decoy ODN group respectively. **p < 0.01
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analysis. However, we found the expression of α-SMA 
and COLIα2 genes was further down-regulated by the 
combination of SP1 and UTE1 Decoy ODNs. The para-
dox requires further study. The excessive accumulation of 
ECM is derived from the imbalance of its synthesis and 
degradation [25]. The activation of TGF-β signal pathway, 
always mentioned for its association with ECM synthesis, 
regulates the expression of its target genes, such as col-
lagen I, α-SMA and TIMP1. On the other hand, TIMP1 
forms inhibitory complex with MMPs to prevent ECM 
from being degraded by active forms of MMPs [9].
ECM is mainly degraded by MMPs, including MMP2 
and MMP9 [26] and this process can be inhibited by 
TIMP1 [27]. TIMP1 transgenic mice hardly engage hepatic 
fibrosis without any treatment, however, hepatic fibrosis 
can be induced easily dealing with CCl4 and an active form 
of MMP2 level in the liver decreases. Thus, TIMP-1 can 
strongly promote hepatic fibrosis development through 
forming an inhibitory complex with MMP2 [28]. Latest 
research found TIMP1 significantly enhanced expression 
of TGFβ1, α-SMA, collagen I and induced transformation 
of fibroblasts into myofibroblasts in urethral scar [29]. In 
the promoter of TIMP1 gene, there presents a regulatory 
element (5′-TGTGGTTTCCG-3′) which can be bound 
by transcription factor UTE1 [30] and three GC-rich 
motifs for SP1. The activity of these regulatory elements 
in promoter of TIMP1 gene could be inhibited effectively 
by UTE1 Decoy ODN or SP1 Decoy ODN in our experi-
ment. Although the expression of TIMP1 did not obvi-
ously change dealing with single Decoy ODN, it could be 
down-regulated effectively by the combination of SP1 and 
UTE1 Decoy ODNs. In addition, MMP2 and MMP9 were 
not affected by single or combination of Decoy ODNs. 
Taken together, we discover that the combination of SP1 
and UTE1 Decoy ODNs can effectively down-regulate the 
expression of COLIα2 and α-SMA, and the reasonable 
explanation is the combination can increase active forms 
of MMPs by inhibiting the activity of TIMP1.
TGF-β, a central regulator in chronic liver disease, con-
tributes to fibrogenesis through inflammation and acts 
as an autocrine anabatic regulator for ECM production 
in the activated HSCs [31]. In HCV infection, TGF-β 
promoter activation is regulated by transcription fac-
tors SP1, AP-1, STAT-3, and NF-kB and the activation 
of these transcription factors is related to the activation 
of cellular kinases [32]. TGF-β can promote the expres-
sion of its target genes, α-SMA and collagen I, through 
Smad2/3/4 complex binding to TRE which is an enhancer 
of TGF-β target genes. Although SP1 and UTE1 Decoy 
ODNs could not down-regulate the expression of TGF-β, 
we found they could influence the activation of TRE. Fur-
thermore, we observed that the combination of SP1 and 
UTE1 Decoy ODNs had a more powerful influence on 
the expression of α-SMA and COLIα2, but no different 
influence on the activation of TRE compared with single 
ODN. Thus, it may be part of the causes for the down-
regulations of the expression of α-SMA and COLIα2 
through TGF-β signal pathway being acted by the com-
bination of SP1 and UTE1 Decoy ODNs. It also suggests 
that the combination of SP1 and UTE1 Decoy ODNs 
correct the inbalance of α-SMA and ECM from synthe-
sis and degradation through TIMP1 and TGF-β signal 
pathway but not the expression of TGF-β itself. It need 
to further explore is that there are no binding sites in the 
promoters of gene α-SMA, COLIα2 and TGF-β for UTE1 
by bioinformatics analysis, however, the treatment of 
UTE1 decoy ODN still has great impact at the expression 
level of these genes. In human fibroblasts of urethral scar 
as previously mentioned [29], overexpression of TIMP1 
significantly enhanced expression of TGF-β, α-SMA, col-
lagen I and induced transformation of fibroblasts into 
myofibroblasts, while inhibition of TIMP-1 by lentivi-
ruses carrying a transgene or a short hairpin small inter-
fering RNA for TIMP-1 significantly decreased TGF-β, 
α-SMA and collagen I levels. In our study, the expression 
of TIMP1 can be down-regulated by UTE1 Decoy ODN. 
It is a possible reason that the declined endogenous 
TIMP1 by UTE1 Decoy ODN leads to the down-regu-
lated activity of the luciferase reporter gene of TGF-β, 
α-SMA and collagenIα2. Of course, it is worth further 
confirming mechanism in the future.
Recent studies have shown that TIMP1 plays an impor-
tant role in colorectal cancer progression [33] and the 
expression of TIMP1 in HCC tissues is in consistent 
with cancer cell proliferation and advanced TNM stage 
[34]. Popov found that apoptosis of activated cholangio-
cytes and their subsequent macrophage mediated clear-
ance were in favor of fibrosis reversal [35]. Host-derived 
TIMP1 can promote liver metastasis by inducing hepato-
cyte growth factor signaling which is conducive to liver 
proliferation [36]. SP1 plays an important regulatory role 
in cell proliferation [37] and SP1 Decoy ODN inhibits cell 
proliferation of hypertrophic scar fibroblasts [38]. SP1 
Decoy ODN also can inhibit the proliferation of HSCs 
through down-regulating the expression of cyclin D1 and 
p27 [17]. Our research has shown that SP1 and UTE1 
Decoy ODNs can inhibit HSC-T6 cell proliferation at 72 h 
but not 24 or 48 h. In a rabbit model, α-SMA-positive cell 
proliferation was inhibited through capturing both NFκB 
and E2F simultaneously by chimeric Decoy ODN [38]. 
Here, we have proved the combination of SP1 and UTE1 
Decoy ODNs can restrain HSC-T6 cell proliferation at 
72  h but not 24 or 48  h. Taken together, our study has 
declared that the combination of SP1 and UTE1 Decoy 
ODNs can inhibit the activation and proliferation of 
HSCs more effectively than one of Decoy ODNs through 
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co-regulation of TIMP1 and TGF-β signal pathway but 
not the expression of TGF-β itself.
Methods
Synthesis of oligodeoxynucleotides (ODNs) and plasmid 
construction
The Decoy ODNs and scrambled (Scr) Decoy ODN 
(Table  1) were synthesized by Sangon Biotech (Shang-
hai, China). These Decoy ODNs were annealed overnight 
while the temperature decreased from 100 °C to 25 °C.
Eukaryotic expression plasmid pGLuc-TRE-MiniTK 
was constructed when TGF-β responsive element (TRE) 
was cloned into the pGLuc-Mini-TK (BioLab, UK). 
Eukaryotic expression plasmids pGLuc-PSMA, pGLuc-
P-COLΙα2 and pGLuc-P-TIMP1 were constructed when 
promoters of α-SMA (PSMA), COLΙα2 (P-COLΙα2) and 
TIMP1 (P-TIMP1) were also cloned into the pGLuc-
Basic vector (N8082S, NEB, United States), respectively, 
for luciferase assays.
HSC‑T6 cell culture, transfection and luciferase reporter 
assays
HSC-T6 cells, an immortalized rat HSC line provided 
by the institute of liver disease at Shanghai University of 
Traditional Chinese Medicine, were cultured in high glu-
cose DMEM (invitrogen) supplemented with 10  % new-
born calf serum (NBCS). HSC-T6 cells were seeded in a 
6-well-plate (Greiner, Germany) for western bolt assay or 
24-well-plate (Greiner, Germany) for PCR or luciferase 
assays or 96-well-plate (Greiner, Germany) for MTT assay 
at 60 % confluence per well and cultivated in a humidified 
atmosphere containing 5 % CO2 for 24 h at 37 °C.
After plasmids were transfected into HSC-T6 cells 
using the Tubofect Transfection Reagent (Thermo) 
according to the manufacturer’s instructions for 24  h, 
respectively, cells were transfected with different Decoy 
ODNs(the concentration of SP1, UTE1 and Scr decoy 
ODN was 20 Nm/L, and the concentration of the decoy 
ODNs combination was also 20  Nm/L, containing 
10 Nm/L of each single ODN) using the Mirus Transfec-
tion Reagent (Mirus Bio Corporation) for another 24 h. 
For luciferase assays, the supernatants were collected 
and the assays were performed using the Gaussia Lucif-
erase Assay Kit (BioLux) according to the manufacturer’s 
instructions. The reactions were examined using a Fluo-
rescence Detector (Brethold).
Western blot analysis
Cells were collected for western blot assay after Decoy 
ODNs were transfected into HSC-T6 cells for 48 h. Then 
cells were lysed in lysis buffer (25 mmol/L Tris–HCl pH 
7.5, 2.5  mmol/L EDTA, 137  mmol/L NaCl, 2.7  mmol/L 
KCl, 1  % sodium deoxycholic acid, 0.1  % SDS, 1  % Tri-
tonX-100, and 2  mmol/L PMSF) and protease inhibitor 
cocktail for 30 min at 4 °C. The cell lysates were clarified 
by centrifugation at 12,000 rpm for 20 min at 4 °C, and the 
supernatants were collected. The protein concentrations 
were measured using a BCA Protein Assay kit (Thermo). 
An equal amount of protein from each sample was sep-
arated by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to a polyvi-
nylidene difluoride membrane. The membrane was incu-
bated with a mouse monoclonal anti-α-SMA antibody 
(1:1000 dilution) (Sigma), a rabbit polyclonal anti-TGF-β 
antibody (1:1000 dilution) (SANTA CRUZ), a goat mono-
clonal anti-(TIMP1, MMP2, COLΙα2) antibody (1:1000 
dilution) (SANTA CRUZ) and a mouse monoclonal anti-
β-actin antibody (1:3000 dilution) (Sigma) overnight at 
4  °C. This primary antibody incubation was followed by 
incubation with HRP-conjugated anti-mouse (1:3000 
dilution), anti-rabbit (1:3000 dilution) or anti-goat (1:8000 
dilution) antibody as the secondary antibody for 1  h at 
room temperature. These membranes were developed 
using Immobilon Western Detection Reagents (Millipore) 
according to the manufacturer’s instructions. The chemi-
luminescence on the membrane was detected using the 
VersaDoc system (Bio-Rad). Densitometric analyses of the 
band intensities were performed using ImageJ software 
(version 1.38×; National Institutes of Health).
Cell proliferation assay
After HSC-T6 cells were dealt with 20  nM of Decoy 
ODNs in triplicate for 24, 48 and 72 h, 50 μl MTT solu-
tion (250 μg/ml in DMEM) was added into each well and 
the cells were incubated at 37 °C for 4 h. When the plates 
were centrifuged at 380×g for 10  min, the supernatant 
medium was removed and then 200  μl of dimethylsul-
foxide was added to each well for another 20  min. The 
absorbance (A) of each well at 490 nm was recorded. The 
cell survival rate was calculated according to the follow-
ing formula: Cell survival rate (%) = ADecoy/Acontrol × 100.
Statistical analysis
Data are presented as mean ± standard error (SE) of sev-
eral experiments. Difference between two groups was 
analyzed by a two-tailed Student’s t test, and difference 
between three or more groups was analyzed by one-way 
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ANOVA multiple comparisons. p < 0.05 was considered 
statistically significant.
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